RT Journal Article
SR Electronic
T1 Association between high serum favipiravir concentrations and drug-induced liver injury
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.03.21256437
DO 10.1101/2021.05.03.21256437
A1 Hitoshi Kawasuji
A1 Yasuhiro Tsuji
A1 Chika Ogami
A1 Yusuke Takegoshi
A1 Makito Kaneda
A1 Yushi Murai
A1 Kou Kimoto
A1 Akitoshi Ueno
A1 Yuki Miyajima
A1 Yasutaka Fukui
A1 Kentaro Nagaoka
A1 Ippei Sakamaki
A1 Yoshitomo Morinaga
A1 Yoshihiro Yamamoto
YR 2021
UL http://medrxiv.org/content/early/2021/05/04/2021.05.03.21256437.abstract
AB Objectives This study aimed to evaluate the incidence and pattern of favipiravir-induced liver injury and the potential association between serum concentrations in hospitalized COVID-19 patients.Patients and methods We retrospectively reviewed laboratory-confirmed patients with COVID-19 for whom serum favipiravir trough concentration (Cmin) was measured under steady-state conditions during treatment. All patients were administered 1800 mg of favipiravir twice daily on the first day and 800 mg twice daily from the second day.Results Thirty observed favipiravir concentrations were collected from nine patients. Of these, favipiravir-induced liver injury developed in three patients after 13 (11–14) days from the initiation of therapy, with two classified as cholestatic and one hepatocellular injury, with a score of four (possible), seven (probable), and three (possible) based on the CIMOS/RUCAM scoring system. Median (range) favipiravir Cmin at steady state was found to be significantly higher in patients with liver injury at 66.4 (47.8–72.4) mg/L than in those without injury at 12.8 (9.4–21.8) mg/L (P = 0.028).Conclusions Higher favipiravir serum concentrations were observed in patients who developed favipiravir-induced liver injury than in those who did not. As the variations in favipiravir concentrations between patients were large, personalized optimal dosing strategies may be needed for safe use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED) grant number JP20he0622035, and Japan Society for the Promotion of Science (JSPS) KAKENHI grant numbers JP18J23248 and JP19K08950.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed as per the Declaration of Helsinki and was approved by the Ethical Review Board of the University of Toyama (approval numbers: R2019167 and R2020146) and Nihon University (School of Pharmacy, approval number: 20-005). Written informed consent was obtained from all patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A